Skip to main content

Stanford’s Laboratory for Cell and Gene Medicine aims to ‘cure the incurable’

When you read about initiatives like Stanford University’s new Laboratory for Cell and Gene Medicine, it’s difficult to think of too many other places on Earth where more exciting — and potentially life-changing — work is being done.

Opened in September, the 25,000-square-foot facility is currently attacking a number of the world’s most challenging medical problems. As laboratory director Dr. David DiGiusto puts it, it’s all about “curing the incurable.”

Recommended Videos

“Many diseases cannot be cured with conventional therapies that are palliative only in nature,” laboratory director DiGiusto told Digital Trends. “Other diseases have no effective treatments at all. Our mission is to develop and test cures for incurable diseases using cell and gene therapy. We are currently working on cancer, monogenic disease (i.e., SCID, sickle cell, and other immune deficiencies), and regenerative medicine [like] dermatology, neurosciences, and cardiovascular medicine.”

Image used with permission by copyright holder

The lab is currently carrying out a range of exciting projects in its “clean rooms.” These include sheets of genetically corrected skin that can be given as skin grafts to patients suffering from the blistering skin disease epidermolysis bullosa, in which layers of skin don’t adhere properly to the body. There are also projects to regenerate corneal cells in the eye, repair mutations in blood cells, genetically engineer immune system T cells to fight cancer, and more.

As DiGiusto points out, these efforts have the possibility to “end great suffering if ultimately successfully commercialized.”

While there are other laboratories around the U.S. working on projects like cell-based approaches to cancer, what is impressive about Stanford’s efforts is the massive scale. A bit like legendary research facilities such as Xerox PARC — where much of the technology behind the personal computer revolution was invented — there are so many interesting projects being carried out at the Laboratory for Cell and Gene Medicine that it’s difficult to name them all.

Suffice it to say that if you hadn’t heard of the lab before now, that will almost certainly change over the coming years.

“There are now quite a few academic manufacturing facilities supporting [similar] efforts but most are working on only two or three products,” DiGiusto said. “Stanford has a broad portfolio of candidate cell and gene therapies that we will likely have eight to 10 products in the queue at all times. Because Stanford has the basic science, translational, and manufacturing capability, and 2 hospitals focused on clinical research — Stanford Health Care and Lucile Packard Children’s Hospital — we have a tremendous infrastructure in place to develop and test a wide array of candidate therapies. The magnitude of the effort is quite significant.”

Luke Dormehl
I'm a UK-based tech writer covering Cool Tech at Digital Trends. I've also written for Fast Company, Wired, the Guardian…
Sebastian Stan lays out Bucky’s future after Thunderbolts
Sebastian Stan in Thunderbolts.

There are some spoilers ahead for the ending of Marvel's Thunderbolts. Stop reading now if you don't want to be spoiled.

Earlier this year, Captain America: Brave New World briefly introduced a new direction for James "Bucky" Barnes, a character Sebastian Stan has been playing since 2011 in Captain America: The First Avenger. In Brave New World, the former Winter Soldier apparently retired from being a reformed hero and went into politics by running for Congress. Thunderbolts reveals that Bucky won his election to the House of Representatives. But his stay in Congress was short.

Read more
Jeep Compass EV breaks cover—but will it come to the U.S.?
jeep compass ev us newjeepcompassfirsteditionhawaii  4

Jeep just pulled the wraps off the all-new Compass EV, and while it’s an exciting leap into the electric future, there's a catch—it might not make it to the U.S. anytime soon.
This is a brand new electric version of the Jeep Compass, and being built on Stellantis' STLA platform—the same architecture underpinning models like the Peugeot E-3008 and E-5008—it looks much slicker and packs a lot more inside than previous versions of the Compass.
Let’s start with what’s cool: the new Compass EV is packing up to 404 miles of range on a single charge, a 74 kWh battery, and fast-charging that gets you from 20% to 80% in about 30 minutes. Not bad for a compact SUV with Jeep's badge on the nose.
There are two versions: a front-wheel-drive model with 213 horsepower and a beefier all-wheel-drive version with 375 horsepower. That AWD setup isn’t just for looks—it can handle 20% inclines even without front traction, and comes with extra ground clearance and better off-road angles. In short, it’s still a Jeep.
The design's been refreshed too, and inside you’ll find the kind of tech and comfort you’d expect in a modern EV—sleek, smart, and ready for both city streets and dirt trails.
But here’s the thing: even though production starts soon in Italy, Jeep hasn’t said whether the Compass EV is coming to America. And the signs aren’t promising.
Plans to build it in Canada were recently put on hold, with production now delayed until at least early 2026. Some of that might have to do with possible U.S. tariffs on Canadian and Mexican vehicles—adding a layer of uncertainty to the whole rollout.
According to Kelley Blue Book, a Stellantis spokesperson confirmed that the company has “temporarily paused work on the next-generation Jeep Compass, including activities at” the Canadian plant that was originally meant to build the model. They added that Stellantis is “reassessing its product strategy in North America” to better match customer needs and demand for different powertrain options.
So while Europe and other markets are gearing up to get the Compass EV soon, American drivers might be left waiting—or miss out entirely.
That’s a shame, because on paper, this electric Jeep hits a lot of sweet spots. Let’s just hope it finds a way over here.

Read more
Charlie Cox singles out his least favorite Daredevil: Born Again episode
Charlie Cox in Daredevil: Born Again.

Daredevil: Born Again season 1 was largely reconceived after the 2023 actor and writer strikes. Dario Scardapane -- a veteran of The Punisher series on Netflix -- was brought in to be the new showrunner and he made a lot of changes to the series that were well-received. However, there's one episode that Scardapane didn't really change at all, and it happens to be the least favorite episode of Daredevil: Born Again's leading man, Charlie Cox.

During an appearance on The Playlist, Cox noted that he wasn't very fond of the season's fifth episode, "With Interest," which was a largely standalone episode that featured his character, Matt Murdock, in a bank during a hostage crisis.

Read more